Mohamed Abdelsalam | Interventional Radiology | Best Researcher Award

Published on by Global Academic Awards

Assoc. Prof. Dr. Mohamed Abdelsalam | Interventional Radiology | Best Researcher Award

The University of Texas MD Anderson Cancer center | United States

Assoc. Prof. Dr. Mohamed Abdelsalam is a highly accomplished Interventional Radiologist at The University of Texas MD Anderson Cancer Center, currently serving as Associate Professor after joining as Assistant Professor in 2016. He earned his MBBS (Magna Cum Laude) from Cairo University Faculty of Medicine and completed advanced training including a Clinical Residency in Diagnostic Radiology and a Clinical Fellowship in Vascular Interventional Radiology at MD Anderson. Assoc. Prof. Dr. Mohamed Abdelsalam has extensive professional experience, including roles as Visiting Scientist, Assistant Lecturer, and Assistant Medical Director at Cairo University and affiliated institutions. He is board-certified in Diagnostic and Interventional Radiology and holds multiple DEA and Texas Medical Board licenses. His research focuses on image-guided oncologic interventions, vascular procedures, and minimally invasive cancer therapies, with notable contributions in radiofrequency ablation, thrombectomy, and renal tumor management. With 37 Scopus-indexed publications, 288 citations, and an h-index of 11, he has received several honors, including Teaching IR Physician of the Year (2020) and Distinguished Abstract Award (SIR, 2013), reflecting his impact in both clinical practice and research.

Profile: Scopus

Featured Publications

  • Abdelsalam, M. E., et al. (2025). Technical effectiveness and clinical outcomes of mechanical thrombectomy in cancer patients presenting with IVC filter–associated deep venous thrombosis: A retrospective study. Annals of Vascular Surgery.

  • Abdelsalam, M. E., et al. (2025). Cystoscope assisted trans-conduit removal of fragmented percutaneous nephrostomy catheter. Urology Case Reports.

  • Abdelsalam, M. E., et al. (2025). Technique and outcomes of radiofrequency ablation of biopsy-proven 3–4 cm T1a renal cell carcinoma. Biomedicines.